BridgeBio Pharma Stock Target Price and Analyst Consensus
BBIO Stock | USD 30.78 0.08 0.26% |
The current analyst and expert consensus on BridgeBio Pharma is Strong Buy, with 8 strong buy opinions. The current projected BridgeBio Pharma target price consensus is 46.4 with 14 analyst opinions. The most common way BridgeBio Pharma analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview BridgeBio Pharma executives and customers to further validate their buy or sell advice. BridgeBio Pharma buy-or-sell recommendation module provides average expert sentiment on the projected BridgeBio Pharma target price to derive its highest and lowest estimates based on its projected price volatility. Check out Macroaxis Advice on BridgeBio Pharma to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.
Lowest Forecast 42.22 | Highest Forecast 51.5 | Target Price 46.4 |
BridgeBio |
It's important to approach BridgeBio Pharma's target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
BridgeBio Pharma Target Price Consensus
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. BridgeBio target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. BridgeBio Pharma's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
14 | Strong Buy |
Most BridgeBio analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand BridgeBio stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of BridgeBio Pharma, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationBridgeBio Pharma Target Price Projection
BridgeBio Pharma's current and average target prices are 30.78 and 46.40, respectively. The current price of BridgeBio Pharma is the price at which BridgeBio Pharma is currently trading. On the other hand, BridgeBio Pharma's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
BridgeBio Pharma Market Quote on 28th of March 2024
Target Price
Analyst Consensus On BridgeBio Pharma Target Price
BridgeBio Pharma Analyst Ratings
BridgeBio Pharma's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about BridgeBio Pharma stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of BridgeBio Pharma's financials, market performance, and future outlook by experienced professionals. BridgeBio Pharma's historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize BridgeBio Pharma price targets
BridgeBio Pharma's stock target price is an estimate of its future price, usually made by analysts. Using BridgeBio Pharma's target price to determine if it is a suitable investment can be done through the following steps:- Look at BridgeBio Pharma's target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if BridgeBio Pharma's stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional BridgeBio Pharma Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of BridgeBio Pharma is a key component of BridgeBio Pharma valuation and have some predictive power on the future returns of a BridgeBio Pharma.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of BridgeBio Pharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.Corona Opportunity Invested few shares | ||
Adviser Favorites Invested a lot of shares | ||
Business Services Invested over 100 shares | ||
Warren Buffett Holdings Invested few shares | ||
Hedge Favorites Invested over 40 shares | ||
Momentum Invested few shares | ||
ESG Investing Invested few shares | ||
Tech Growth Invested over 100 shares | ||
FinTech Invested over 70 shares | ||
Millennials Best Invested over 30 shares | ||
Technology Invested a lot of shares | ||
Driverless Cars Invested over 50 shares | ||
Software Invested few shares | ||
Check out Macroaxis Advice on BridgeBio Pharma to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for BridgeBio Stock analysis
When running BridgeBio Pharma's price analysis, check to measure BridgeBio Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BridgeBio Pharma is operating at the current time. Most of BridgeBio Pharma's value examination focuses on studying past and present price action to predict the probability of BridgeBio Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BridgeBio Pharma's price. Additionally, you may evaluate how the addition of BridgeBio Pharma to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency |
The data published in BridgeBio Pharma's official financial statements usually reflect BridgeBio Pharma's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of BridgeBio Pharma. For example, before you start analyzing numbers published by BridgeBio accountants, it's critical to develop an understanding of what BridgeBio Pharma's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of BridgeBio Pharma's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BridgeBio Pharma's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in BridgeBio Pharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BridgeBio Pharma. Please utilize our Beneish M Score to check the likelihood of BridgeBio Pharma's management manipulating its earnings.